Urgent Need for Increased Awareness of Disease, Funding for Research
SAN JOSE, Calif., Oct. 31 /PRNewswire-USNewswire/ -- Actor Robert Goulet was unfortunately one of 40,000 people in the U.S. who will lose their lives to idiopathic pulmonary fibrosis (IPF) this year, the same number as will die from breast cancer. Yet, most people have never heard of IPF until someone they love is diagnosed.
IPF has no FDA approved treatment, no known cause and no cure. As in Goulet's case, most patients won't receive a potentially life saving lung transplant in time. In fact, approximately 50 percent of IPF patients who are on a lung transplant list will pass away before a donor lung becomes available.
More than 128,000 people suffer from IPF in the United States, and prevalence and incidence of the deadly disease has increased more than 150 percent in just five years.
"Our sympathies go out to the Goulet family. We know first hand the tragedy of IPF," said Mark Shreve, chief executive officer of the Coalition for Pulmonary Fibrosis (CPF). "It is devastating news to IPF patients and their families that viable treatments for IPF still do not exist. We desperately need to increase awareness of IPF and fund research that will lead to new treatments, and ultimately a cure."
"Pulmonary Fibrosis remains an extremely frustrating disease for researchers," said Kevin K. Brown, M.D., senior author of the study and vice chair of medicine at National Jewish Medical & Research Center in Denver. "The devastation it causes to patients and their families only amplifies the urgency we feel as we study the disease. While we have made some progress over the last decade, it is not nearly enough."
About Idiopathic Pulmonary Fibrosis (IPF)
IPF is a lung disorder characterized by a progressive scarring - known
as fibrosis - and deterioration of the lungs, which slowly robs its victims
of their ability to breathe. Approximately 128,000 Americans suff
|SOURCE Coalition for Pulmonary Fibrosis|
Copyright©2007 PR Newswire.
All rights reserved